As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...
The support is designed to speed development of well-matched H5N1 vaccines and pave the way for vaccines against other ...
Hosted on MSN21h
Moderna Stock Jumps On $590M US Award For Bird Flu Vaccine Development, But Retail Doubts Longevity Under TrumpShares of Moderna Inc. rose over 5% on Tuesday morning, reaching levels last seen more than a week ago, following news of a ...
Yesterday the World Health Organization (WHO) said Tanzania has 1 confirmed case of Marburg and 25 suspected cases all from ...
U.S. equities rose at midday on optimism the new tariffs threatened by President Trump won't be as severe as initially believed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback